Long-Term Outcomes after Surgery for Pheochromocytoma and Sympathetic Paraganglioma
暂无分享,去创建一个
F. Galuppini | F. Ceccato | M. Iacobone | F. Crimi’ | S. zovato | F. Torresan | D. Schiavone | Arianna Beber | F. Crimì
[1] P. Dahia,et al. Update on the genetics of paragangliomas , 2023, Endocrine-related cancer.
[2] M. Elston,et al. Systematic Review: Incidence of Pheochromocytoma and Paraganglioma Over 70 Years , 2022, Journal of the Endocrine Society.
[3] F. Beuschlein,et al. Determinants of disease-specific survival in patients with and without metastatic pheochromocytoma and paraganglioma. , 2022, European journal of cancer.
[4] A. Tischler,et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas , 2022, Endocrine Pathology.
[5] M. Papotti,et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms , 2022, Endocrine Pathology.
[6] E. Baudin,et al. Recurrence-free survival analysis in locally advanced pheochromocytoma: first appraisal. , 2021, The Journal of clinical endocrinology and metabolism.
[7] K. Dreijerink,et al. Recurrence rate of sporadic pheochromocytomas after curative adrenalectomy - a systematic review and meta-analysis. , 2020, The Journal of clinical endocrinology and metabolism.
[8] C. Stratakis,et al. Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents , 2020, Journal of Cancer Research and Clinical Oncology.
[9] A. Lacroix,et al. Postoperative Recurrences in Patients Operated for Pheochromocytomas and Paragangliomas: New Data Supporting Lifelong Surveillance , 2017, Cancers.
[10] R. Lloyd,et al. WHO classification of tumours of endocrine organs , 2017 .
[11] J. Lenders,et al. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis. , 2016, European journal of endocrinology.
[12] O. Dekkers,et al. European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.
[13] W. Young,et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.
[14] J. Lenders,et al. Pathophysiology and diagnosis of disorders of the adrenal medulla: focus on pheochromocytoma. , 2014, Comprehensive Physiology.
[15] S. Bornstein,et al. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. , 2012, European journal of cancer.
[16] M. Fassnacht,et al. Long-term Postoperative Follow-up in Patients with Apparently Benign Pheochromocytoma and Paraganglioma , 2012, Hormone and Metabolic Research.
[17] A. Fassina,et al. Is genetic screening indicated in apparently sporadic pheochromocytomas and paragangliomas? , 2011, Surgery.
[18] Lei Feng,et al. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators. , 2011, The Journal of clinical endocrinology and metabolism.
[19] Choung-Soo Kim,et al. Predictive Characteristics of Malignant Pheochromocytoma , 2009, Korean journal of urology.
[20] A. Verbeek,et al. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma. , 2008, Endocrine-related cancer.
[21] J. Lew,et al. Outcomes of Pheochromocytoma Management in the Laparoscopic Era , 2007, Annals of Surgical Oncology.
[22] G. Hansson,et al. Long‐term outcome of a large series of patients surgically treated for pheochromocytoma , 2005, Journal of internal medicine.
[23] G. Chatellier,et al. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. , 2005, The Journal of clinical endocrinology and metabolism.
[24] L. Thompson. Pheochromocytoma of the Adrenal Gland Scaled Score (PASS) to Separate Benign From Malignant Neoplasms: A Clinicopathologic and Immunophenotypic Study of 100 Cases , 2002, The American journal of surgical pathology.
[25] N. Abumrad,et al. Clinical experience over 48 years with pheochromocytoma. , 1999, Annals of surgery.
[26] J. Cooper. Ajcc Cancer Staging Manual , 1997 .